Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $465.8 million.

  • Pharming's Total Liabilities rose 1150.6% to $465.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $465.8 million, marking a year-over-year increase of 1150.6%. This contributed to the annual value of $392.2 million for FY2024, which is 1383.37% down from last year.
  • Pharming's Total Liabilities amounted to $465.8 million in Q3 2025, which was up 1150.6% from $438.4 million recorded in Q2 2025.
  • Pharming's 5-year Total Liabilities high stood at $420.4 billion for Q1 2021, and its period low was $393671.3 during Q4 2021.
  • In the last 5 years, Pharming's Total Liabilities had a median value of $416.6 million in 2023 and averaged $44.9 billion.
  • Over the last 5 years, Pharming's Total Liabilities had its largest YoY gain of 9542692.01% in 2022, and its largest YoY loss of 9990.83% in 2022.
  • Pharming's Total Liabilities (Quarter) stood at $393671.3 in 2021, then skyrocketed by 97117202.26% to $382.3 billion in 2022, then plummeted by 99.88% to $455.2 million in 2023, then dropped by 13.83% to $392.2 million in 2024, then increased by 18.77% to $465.8 million in 2025.
  • Its last three reported values are $465.8 million in Q3 2025, $438.4 million for Q2 2025, and $187.9 million during Q1 2025.